Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
Grant Information: | HL-33721 United States HL NHLBI NIH HHS; HL-44612 United States HL NHLBI NIH HHS; K08-HL-02858 United States HL NHLBI NIH HHS; etc. |
---|---|
Substance Nomenclature: | 0 (Crotalid Venoms) 0 (Hemagglutinins) 0 (Platelet Glycoprotein GPIb-IX Complex) 0 (Recombinant Proteins) 0 (von Willebrand Factor) 1404-55-3 (Ristocetin) 85537-36-6 (botrocetin) 9007-34-5 (Collagen) 9007-49-2 (DNA) |
Entry Date(s): | Date Created: 19980321 Date Completed: 19980316 Latest Revision: 20210216 |
Update Code: | 20240829 |
PMID: | 9473222 |
Autor: | Hillery CA; Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, WI 53233, USA., Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR |
Jazyk: | angličtina |
Zdroj: | Blood [Blood] 1998 Mar 01; Vol. 91 (5), pp. 1572-81. |
Abstrakt: | von Willebrand disease (vWD) is a common, autosomally inherited, bleeding disorder caused by quantitative and/or qualitative deficiency of von Willebrand factor (vWF). We describe two families with a variant form of vWD where affected members of both families have borderline or low vWF antigen levels, normal vWF multimer patterns, disproportionately low ristocetin cofactor activity, and significant bleeding symptoms. Whereas ristocetin-induced binding of plasma vWF from affected members of both families to fixed platelets was reduced, botrocetin-induced platelet binding was normal. The sequencing of genomic DNA identified unique missense mutations in each family in the vWF exon 28. In Family A, a missense mutation at nucleotide 4105T --> A resulted in a Phe606Ile amino acid substitution (F606I) and in Family B, a missense mutation at nucleotide 4273A --> T resulted in an Ile662Phe amino acid substitution (I662F). Both mutations are within the large disulfide loop between Cys509 and Cys695 in the A1 domain that mediates vWF interaction with platelet glycoprotein Ib. Expression of recombinant vWF containing either F606I or I662F mutations resulted in mutant recombinant vWF with decreased ristocetin-induced platelet binding, but normal multimer structure, botrocetin-induced platelet binding, collagen binding, and binding to the conformation-sensitive monoclonal antibody, AvW-3. Both mutations are phenotypically distinct from the previously reported variant type 2MMilwaukee-1 because of the presence of normal botrocetin-induced platelet binding, collagen binding, and AvW-3 binding, as well as the greater frequency and intensity of clinical bleeding. When the reported type 2M mutations are mapped on the predicted three-dimensional structure of the A1 loop of vWF, the mutations cluster in one region that is distinct from the region in which the type 2B mutations cluster. |
Databáze: | MEDLINE |
Externí odkaz: |